京新药业：公司的盐酸卡利拉嗪胶囊已经提交了上市申请

Core Viewpoint - The company has submitted a listing application for its hydrochloride cariprazine capsules, which currently do not meet the criteria for priority review, and is preparing to cooperate with regulatory approval processes to expedite market entry for new treatment options for patients [1] Group 1 - The listing application for hydrochloride cariprazine capsules has been submitted [1] - The project does not currently meet the priority review criteria [1] - The company is committed to preparing and cooperating with regulatory approval processes [1]